Hi everyone,
Last month brought meaningful movement at the policy level. This month, we are going deeper into the under-recognized intersection of hormonal decline and allergic disease. We are also expanding this newsletter in a direction several of you have asked about. Two new sections join the regular clinical roundup: one on practice development for independent clinicians, and one on AI at the point of care.
Here’s a quick summary of this month’s topics::
✔️ Menopause and Allergic Diseases: Hormonal decline modifies the onset, severity, and treatment response of at least nine allergic conditions, including asthma, anaphylaxis, urticaria, and drug hypersensitivity. Clinically, this suggests that a patient may develop asthma for the first time in menopausal transition (related mechanisms described below). 2026 Review, Frontiers in Allergy
✔️ More and more physicians are going independent, and patient acquisition is on their minds: Interactive assessments on clinic websites convert visitors to booked appointments at 4–5x the rate of static contact forms. Word of mouth, in-person events, and cross-professional referrals consistently outperform paid digital ads - but only when built as deliberate systems rather than left to chance.
✔️ Among clinicians using Dama Assist most effectively, the highest-value use case isn't just document generation or drug lookup - it's clinical reasoning and research synthesis. Using AI to think through a complex case, refine a differential, or synthesize emerging evidence before walking into the room produces a different category of outcome than using it as a search engine.
Menopause and Allergic Disease: A Clinical Blind Spot:
How often do you ask a perimenopausal patient whether her new-onset eczema, first-ever anaphylaxis, or worsening asthma coincided with her last regular period? The relationship between hormonal decline and allergic disease has historically been a clinical blind spot, leaving clinicians to manage these presentations without a menopause-specific framework.
A recent narrative review published in Frontiers in Allergy synthesizes the current evidence across nine immune-predominant conditions.
The pathophysiology. Estrogen is a master regulator of mast cell activity, Th2 inflammation, mucosal immunity, and epidermal barrier repair. When estrogen drops during the menopausal transition, these systems shift simultaneously:
Mast cell degranulation increases while histamine breakdown slows.
Skin barriers weaken as epidermal ceramide production drops.
Hepatic CYP1A2 activity falls, raising circulating drug levels and triggering reactions that mimic drug hypersensitivity.
Bradykinin degradation is altered, lowering the threshold for angioedema.
Figure 1. Sourced from Frontiers: Impact of menopause on allergic diseases.
Clinical takeaways on what the data show across specific conditions:
The Asthma: Roughly 15–22% of women with asthma are menopausal (1). Interestingly, longitudinal data suggest postmenopausal status (particularly surgical menopause) is linked to new-onset asthma (2). When it comes to MHT, one landmark study found that past use of HRT, but not current use, was associated with severe asthma exacerbations. The most plausible explanation comes down to exogenous estrogen likely offering protective effects during active use, but abrupt withdrawal causes a jarring immune shift, particularly in lean women (who have lower peripheral estrogen) or smokers (who may have had amplified pro-inflammatory estrogen effects). The authors flagged the association as important for mechanistic follow-up but insufficient to suggest changes in current management. Rather, the conclusion of this study supports closer monitoring after initiation, particularly in lean women and smokers (3).
Rhinitis and chronic cough: Approximately 33% of postmenopausal women report a chronic cough lasting >8 weeks, frequently with a negative pulmonary workup (4). The airway inflammation in these women doesn't fit classic allergic phenotypes and often resists standard allergy protocols. Notably, MHT has been linked to increased rhinitis symptoms here (a 1.5-fold higher risk in one cohort, again stronger in lean women) (5,6). Such findings precaution escalating a massive allergy workup for refractory rhinitis or unexplained chronic cough without considering menopausal status as a diagnostic variable.
Anaphylaxis: Menopausal women with anaphylaxis tend to present with cardiovascular-dominant symptoms (hypotension, shock) and delayed recovery, rather than the classic skin hives we are trained to look for first, as a result of Estrogen loss; Estrogen loss impairs endothelial nitric oxide signaling and vasodilatory capacity. Therefore, atypical, cardiovascular-first systemic reactions may warrant suspicion, while consideration of overlapping use of ACE inhibitors and beta-blockers in this demographic is crucial due to severely compounding effects on anaphylaxis severity (7).
Drug hypersensitivity: Hormonal changes and polypharmacy impact drug sensitivity and adverse reactions in women, particularly over the age of 55. Estrogen loss has been shown to modulate liver cytochrome P450 enzymes (specifically CYP1A2 activity), key enzymes involved in drug metabolism. The CYP1A2-mediated mechanism, where activity appears to fall by up to 50% during menopause, was specifically characterized in prednisolone pharmacodynamics, limiting its generalizability across all other drug classes (8). That caveat acknowledged, a meaningful proportion of these patients may be carrying incorrect allergy labels, with pharmacokinetic intolerance misclassified as an immune-mediated allergy. As such, medication review for any patient presenting with intolerances to multiple unrelated drug classes, particularly where those intolerances were never immunologically confirmed, should be considered.
Hereditary angioedema (HAE): The menopausal transition causes heterogeneous shifts in HAE. In a retrospective French multicenter cohort, roughly 39% of women improved post-menopause, 46% stabilized, and 15% worsened. Improvement appears most likely in women who had prior estrogen-sensitive flare-ups (9). The estrogen-bradykinin relationship is the key driver here. Estrogen increases bradykinin production, but when it comes to exogenous hormones, the route is everything. Oral estradiol undergoes first-pass hepatic metabolism, increasing bradykinin and risking life-threatening flares. Transdermal estradiol bypasses the liver and has a far lower impact on bradykinin (and may even have the opposite effect), making it theoretically safer (10,11). Despite the theoretical safety of transdermal patches, most immunologists still recommend avoiding exogenous estrogen altogether in HAE unless absolutely unavoidable. If an HAE patient requires hormonal management for severe vasomotor symptoms, progestins are well-tolerated and are the endorsed, preferred first-line approach (12).
✔️ Clinical Takeaway: Although prospective trials and meta-analyses are limited at this stage, this narrative review suggests that menopausal status and MHT formulations belong in your differential reasoning if a midlife woman presents with new-onset asthma, unexplained chronic cough, atypical anaphylaxis, or suddenly becomes "allergic" to multiple unrelated medications.
Featured in Offcall Opinion: When General AI Tools Fall Short in Women's and Hormone Health, And What Clinicians Can Do About It.
Our co-founder, Dr Cecula, was featured in the Offcall newsletter, where she spoke about a limitation most of you have probably encountered firsthand: general AI tools can be genuinely useful for internal medicine, billing codes, and scribing - but they fall short when it comes to hormone health. The evidence base moves quickly, the clinical nuance is significant, and most models don’t have the specialist clinical knowledge built in for it. Read here about why that gap exists and how we're addressing it with Dama Assist.
Building a Patient Acquisition Engine: What Actually Works for Independent Clinics.
Beyond choosing the right technologies and AI that you trust, independent practice owners are also navigating business, operations and growth.
If you're in private practice (or planning to leave a health system) patient acquisition is probably the question you're losing sleep over. You didn't train for this part. And dancing on tiktok is just not for you. The landscape has shifted: patients are being marketed to by well-funded telehealth platforms spending millions on conversion funnels, influencer campaigns, and UX teams whose entire job is to turn a website visitor into a paying patient in under three minutes. You don’t need to compete with them like for like, but you do need a system. Here's what we consistently see working for independent, successful clinics we work with:
Word of mouth. Referred patients arrive warm and pre-sold on your credibility before they've read a single page of your website. Most clinicians wait for this to happen organically. The ones who grow fastest ask for it directly. A simple "Do you know anyone going through something similar?" at the end of a great visit is not pushy - it's an offer of care to someone who hasn't found you yet.
In-person events are back! A hormone health evening at your clinic, a workshop at a local yoga studio, a lunch-and-learn for a local employer. These create trust that no digital ad can replicate. The key: make sure everyone leaves with a way to stay in your orbit - a QR code to a menopause quiz, a mailing list sign-up, a discount on a first visit. You did the hard work of getting them in the room, now make sure you have a way to follow through.
Get on the right directories. NAMS practitioner finder, DPC Alliance, relevant specialty networks. These are patients already actively searching for someone with your credentials and approach. Being findable here costs nothing but a few minutes of your time.
Build referral relationships beyond medicine. Personal trainers, pelvic floor PTs, therapists, nutritionists - they see your future patients daily, often before those patients know they need you. Classic perimenopause presentations, unexpected weight gain, disrupted sleep, mood instability, declining energy, show up in fitness studios and therapy rooms long before they show up in a specialty menopause clinic.. A mutual referral arrangement with practitioners you trust requires no financial exchange, just a genuine relationship and a clear sense of what you each do.
Optimize your digital front door. This is the piece most independent clinics underinvest in and where the gap with telehealth platforms is most visible. Companies like Midi, Ro, and Hims & Hers have spent years optimizing the patient journey from first click to booked appointment. The experience feels informed, personalized, and easy. Patients now expect that. When they land on your website, they're making a fast judgment about whether you understand their problem. Static contact forms convert at around 2–3%. A well-designed interactive patient assessment, one that walks a visitor through their symptoms, educates them about what they're experiencing, and routes them to the right service, converts at 4-5x more. That's not a marginal improvement. It's a different category of result when it comes to marketing and acquisition. And it gives value to your patient before they have ever spoken to you.
Before you know it, you’ll have more patients than you can handle. The demand is there! But as patients start finding you, make sure your website is ready to convert them, your unique approach is coming across, and you are not missing out on opportunities.
At Dama, we support practices that are looking to optimize for growth and patient acquisition. Get in touch if you'd like to see what that could look like for your practice: elena@damahealth.com
Conclusion.
The research gaps in menopausal allergic disease reflect the same historic under-investment in female-specific disease mechanisms, while the practice and AI content reflects what it looks like to build a clinic, and a clinical workflow, that is positioned to act on that science as it matures. As the evidence moves, the guidelines follow, eventually, and what you do in the meantime is the practice of medicine.
As always, if you made it to the end of this newsletter, thank you! We are thrilled you are part of this community of clinicians driving the forefront of evidence-based women's health.
Until next month,
The Dama Health Team